Merck KGaA Sells Five U.S. CDMO Sites to Lonza
Merck KGaA has reached an agreement to divest five of its contract development and manufacturing (CDMO) facilities located in the United States to Swiss pharmaceutical manufacturer Lonza Group AG. The transaction is valued at an enterprise amount in the low-to-mid triple-digit millions of Swiss francs. The deal involves the transfer of approximately 1,100 employees as part of the strategic exit from these specific U.S. operations. This move allows Merck KGaA to streamline its portfolio while expanding Lonza's manufacturing footprint and capacity within the American market.
Topics: Asset Sale CDMO Manufacturing Sites